Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05209152 · ClinicalTrials.gov registry record · Phase 1
AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia
A Phase 1 study, sponsored by Amgen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT05209152 is a Phase 1 study that was terminated before completion, run by Amgen. The registered enrollment target is 7 participants.
The verdict
NCT05209152, a Phase 1 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
The main objective is to assess the safety, tolerability, and efficacy of AMG 176 as monotherapy and in combination with the 7-day regimen of azacitidine for the treatment of Higher-Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia (HR-MDS/CMML).
Interventions
- DRUG Azacitidine
- DRUG AMG 176
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2022-11-14 |
| Est. Completion | 2023-12-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05209152
The ClinicalTrials.gov registry entry for NCT05209152 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Azacitidine is the first listed.
NCT05209152 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05209152 about?
NCT05209152 is a clinical study titled "AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia". The main objective is to assess the safety, tolerability, and efficacy of AMG 176 as monotherapy and in combination with the 7-day regimen of azacitidine for the treatment of Higher-Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia (HR-MDS/CMML).
What is the current status of trial NCT05209152?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2022-11-14. Estimated completion is 2023-12-19.
What interventions are being tested in trial NCT05209152?
The interventions under investigation include: Azacitidine (DRUG), AMG 176 (DRUG).
Who is sponsoring clinical trial NCT05209152?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.